1. Home
  2. CLLS vs ARCI Comparison

CLLS vs ARCI Comparison

Compare CLLS & ARCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.22

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

ARCI

Archimedes Tech SPAC Partners III Co. Ordinary Share

N/A

Current Price

$9.98

Market Cap

349.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CLLS
ARCI
Founded
1999
2025
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.4M
349.8M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
CLLS
ARCI
Price
$3.22
$9.98
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.33
N/A
AVG Volume (30 Days)
32.4K
22.7K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$9.83
52 Week High
$5.48
$10.06

Technical Indicators

Market Signals
Indicator
CLLS
ARCI
Relative Strength Index (RSI) 37.61 66.09
Support Level $3.05 $9.90
Resistance Level $3.83 $10.06
Average True Range (ATR) 0.17 0.01
MACD -0.03 0.00
Stochastic Oscillator 24.19 71.43

Price Performance

Historical Comparison
CLLS
ARCI

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About ARCI Archimedes Tech SPAC Partners III Co. Ordinary Share

Archimedes Tech SPAC Partners III Co is a blank check company.

Share on Social Networks: